Detecting Heart Attacks In Cardiac Arrest Patients
Apr 11, 2023
2 min read
0
3
0
Carlsbad, California (April 11, 2023) - RCE Technologies, Inc.
Heart disease is a leading cause of death worldwide, and heart attacks are a particularly dangerous form of heart disease. When someone experiences a heart attack, it's crucial to identify and treat it quickly to prevent further damage to the heart and increase the chances of survival. That's why researchers at the University of Washington are working on a new study aimed at improving heart attack identification.
Led by Dr. Geoffrey Nichol, the study will focus on using advanced technology to identify heart attacks in out of hospital cardiac arrest (OHCA) patients. Specifically, the researchers will be using RCE's transdermal biomarker sensor wearable, Infrasensor, to get an early assessment of the patient's Troponin trends, a key biomarker index used by clinicians in diagnosing a heart attack.
Overall, this study has the potential to significantly improve the way we identify and treat heart attacks in OHCA patients. If successful, this study could pave the way for more advanced and effective integration of the wearable with emergency medical services (EMS) in the future.
About RCE.ai:RCE.ai, an innovative artificial intelligence (AI) based medical technology company launched in Carlsbad, Calif., in 2018, is dedicated to early heart attack detection. The company has revolutionized the monitoring of cardiac injury by introducing Infrasensor™, a non-invasive infrared-based wearable device. RCE’s proprietary transdermal approach, enhanced with deep learning techniques, analyzes and associates unique optical signatures with cardiac conditions in real-time. This AI-coupled transdermal approach enables the potential application of RCE’s technology in various emergency care settings and remote monitoring applications. Presently, RCE is engaged in clinical studies to optimize the Infrasensor for clinical use. Through ongoing clinical studies, the company hopes to soon secure FDA approval for its technology, opening the door to making it available for sale in the United States.
For more information, please visit https://rce.ai/contact, follow us on LinkedIn or X (formerly Twitter), or contact RCE Investor Relations at ir@rce.ai
Related Posts
